ADVAIR HFA 230 ug/1

ADVAIR HFA 230 ug/1 is a combination inhaler containing fluticasone propionate and salmeterol xinafoate. It is commonly used for managing asthma and chronic obstructive pulmonary disease (COPD). This metered aerosol provides respiratory relief and is manufactured by GlaxoSmithKline LLC.

ADVAIR HFA 230 ug/1 is primarily used for the maintenance treatment of asthma and to prevent bronchospasm in patients with COPD. The inhaler combines an inhaled corticosteroid and a long-acting beta-agonist to help control airway inflammation and improve breathing. It is often prescribed for individuals who require regular management of their respiratory conditions.

Common effects of ADVAIR HFA 230 ug/1 may include throat irritation, hoarseness, and a dry mouth. Some users might experience headaches or tremors. These effects are generally mild and temporary, but persistent or severe reactions should be discussed with a healthcare provider.

ADVAIR HFA 230 ug/1 should be used as directed by a healthcare professional. It is important to rinse your mouth after each use to reduce the risk of oral thrush. Patients with certain medical conditions, such as heart disease or diabetes, should use this inhaler with caution and under medical supervision.

ADVAIR HFA 230 ug/1 may interact with other medications, including beta-blockers, diuretics, and certain antidepressants. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Additionally, alcohol should be consumed with caution while using this inhaler.